ONCAlert | 2018 SGO Annual Meeting on Women’s Cancer
Videos  >  

Acquired Resistance to Osimertinib in T790M-Positive NSCLC

Geoffrey R. Oxnard, MD
Published Online:4:41 PM, Thu April 20, 2017

Geoffrey R. Oxnard, MD, assistant professor of Medicine, Dana-Farber Cancer Center, Harvard Medical School, discusses a study that found overgrowth of competing resistance mechanisms, such as an acquired KRAS mutation, underlies a poor prognosis subtype of acquire resistance to osimertinib (Tagrisso) in T790M-positive non-small cell lung cancer.
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.